Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mineralys Therapeutics Price Performance

Shares of MLYS stock traded up $0.11 on Tuesday, hitting $13.70. 65,103 shares of the stock traded hands, compared to its average volume of 176,427. Mineralys Therapeutics, Inc. has a 1-year low of $5.85 and a 1-year high of $16.91. The company’s fifty day moving average is $11.89 and its 200 day moving average is $12.42. The company has a market capitalization of $680.19 million, a PE ratio of -6.26 and a beta of 1.93.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the company earned ($0.31) earnings per share. As a group, equities research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current year.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Mineralys Therapeutics in the third quarter valued at approximately $110,000. Nantahala Capital Management LLC lifted its holdings in shares of Mineralys Therapeutics by 60.1% during the second quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock valued at $6,230,000 after purchasing an additional 200,000 shares during the last quarter. Driehaus Capital Management LLC grew its position in Mineralys Therapeutics by 40.4% in the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock worth $3,011,000 after purchasing an additional 74,074 shares during the period. Lion Point Capital LP boosted its stake in shares of Mineralys Therapeutics by 31.7% during the 2nd quarter. Lion Point Capital LP now owns 79,000 shares of the company’s stock worth $924,000 after acquiring an additional 19,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Mineralys Therapeutics during the 2nd quarter worth $145,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Thursday, August 15th.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.